Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4782-4788

  Grundei, T ^a   Vogelsang, H ^a   Ott, K ^a   Mueller, J ^a   Scholz, M ^a   Becker, K ^a   Fink, U ^a   Siewer, J R ^a   Hofler H ^a   Keller, G ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHROMOSOME 17P; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY LOSS; HUMAN; MALE; MICROSATELLITE INSTABILITY; PREDICTION; PRIORITY JOURNAL; STOMACH CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 0034490075     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Cancer statistics, 1994
2. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study
3. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study, 1992
4. Preoperative chemotherapy for stage III-IV gastric carcinoma: Feasibility, response and outcome after complete resection
5. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma
6. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer
7. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
8. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma
9. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma
10. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer
11. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
12. Thymidylate synthase protein expression
13. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy
14. Clues to the pathogenesis of familial colorectal cancer
15. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study
16. Mismatch repair defects in human carcinogenesis
17. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population
18. Microsatellite instability at multiple loci in gastric carcinoma: Clinicopathologic implications and prognosis
19. Microsatellite instability in intestinal- and diffuse-type gastric carcinoma
20. Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history
21. Loss of DNA mismatch repair in acquired resistance to cisplatin
22. The role of DNA mismatch repair in platinum drug resistance
23. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas
24. Loss of heterozygosity and K-ras gene mutations in gastric cancer
25. Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach
26. Allelotype of gastric adenocarcinoma
27. Tumors of the gastrointestinal tract and the pancreas: Histopathology, staging and prognosis
28. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma
29. New developments in the treatment of gastric carcinoma
30. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: A phase II study
31. Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract. Relation to clinicopathological data and family history
32. Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas
33. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas
34. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression
35. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
36. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer
37. Fractional allelic loss in gastric carcinoma correlates with growth patterns
38. High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination
39. Genetic instabilities in human cancers
40. Metabolism and mechanism of action of 5-fluorouracil
41. Binding of the antitumor drug cis-diamminedichloro-platinum(II) (cisplatin) to DNA
42. Genetic instability and darwinian selection in tumors
43. Role of DNA aneuploidy, overexpression of p53 gene product, and cellular proliferation in the progression of gastric cancer
44. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas
45. Cell cycle control and cancer
46. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series
47. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
48. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glcoprotein) gene from multidrug-resistant human cells
49. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany